Research Centre of Applied and Preventive Cardiovascular Medicine, University of Turku, Turku, Finland.
Atherosclerosis. 2011 Jul;217(1):234-9. doi: 10.1016/j.atherosclerosis.2011.03.016. Epub 2011 Apr 9.
Adipose-tissue derived adiponectin has gained a lot of interest as a marker of metabolic syndrome (MetS) and cardiovascular risk. The objective of this study was to assess whether adiponectin levels in young adults predict the incidence of MetS after 6-year follow-up. To gain insight on the interrelations between MetS, adiponectin and cardiovascular risk, we also examined the associations of adiponectin and carotid atherosclerosis according to MetS status.
This analysis was part of a population-based, longitudinal cohort study conducted among 1693 Cardiovascular Risk in Young Finns Study individuals (age 31.9 ± 4.9 years in 2001) participating in follow-ups in 2001 and 2007.
In a multivariable model adjusted for age, sex, MetS components, LDL-cholesterol, CRP, insulin, leptin, smoking and family history of coronary disease, 1-unit increase in baseline adiponectin levels was associated with reduced odds (odds ratio [OR]=0.94, 95% CI 0.89-0.99, P=0.04) of incident MetS. Of the MetS components, adiponectin levels were inversely associated with the incidence of hyperglycemia in multivariable analyses (OR=0.94 (0.90-0.99), P=0.04). When studying the adiponectin×MetS interaction on IMT, we observed a significant interaction when examining IMT in 2001 (r=-0.11 (MetS(-)) vs. r=-0.17 (MetS(+)), P for interaction 0.047) and IMT in 2007 (r=-0.12 (MetS(-)) vs. r=-0.21 (MetS(+)), P for interaction 0.005), suggesting the inverse association between adiponectin and IMT is stronger among those with MetS.
Among young adults, high adiponectin levels were associated with decreased incidence of MetS. Moreover, our data suggest that individuals with MetS are more vulnerable to the proatherogenic effects of low adiponectin levels.
脂肪组织衍生的脂联素作为代谢综合征（MetS）和心血管风险的标志物备受关注。本研究旨在评估年轻人的脂联素水平是否可预测 6 年后 MetS 的发生。为了深入了解 MetS、脂联素和心血管风险之间的相互关系，我们还根据 MetS 状态检查了脂联素与颈动脉粥样硬化的相关性。
该分析是在心血管风险年轻芬兰人研究（年龄 31.9 ± 4.9 岁，2001 年）的一项基于人群的纵向队列研究中进行的，该研究纳入了 1693 名参与者，他们在 2001 年和 2007 年进行了随访。
在调整年龄、性别、MetS 成分、LDL 胆固醇、CRP、胰岛素、瘦素、吸烟和冠心病家族史的多变量模型中，基线脂联素水平每增加 1 个单位，MetS 发生的几率就会降低（比值比 [OR]=0.94，95%CI 0.89-0.99，P=0.04）。在多变量分析中，脂联素水平与高血糖的发生呈负相关（OR=0.94（0.90-0.99），P=0.04）。当研究 adiponectin×MetS 在 IMT 上的交互作用时，我们观察到在 2001 年 IMT 检查（r=-0.11（MetS(-)) vs. r=-0.17（MetS(+))，P 交互作用=0.047）和 2007 年 IMT 检查（r=-0.12（MetS(-)) vs. r=-0.21（MetS(+))，P 交互作用=0.005）时存在显著的交互作用，这表明脂联素与 IMT 之间的负相关关系在患有 MetS 的人群中更强。
在年轻人中，高脂联素水平与 MetS 的发生率降低有关。此外，我们的数据表明，患有 MetS 的个体更容易受到低脂联素水平的促动脉粥样硬化作用的影响。
